Table 1 Patient characteristics

From: Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis

 

Before matching

After matching

 

<75 years

≥75 years

P value

<75 years

≥75 years

P value

Number of patients

2536

703

397

397

Gender, n (%)

   Male

1939 (76.5)

502 (71.4)

0.0060

310 (78.1)

292 (73.6)

0.1357

   Female

597 (23.5)

201 (28.6)

87 (21.9)

105 (26.5)

 

Age, years

62.0 ± 9.1

78.4 ± 3.1

<0.0001

63.0 ± 8.5

78.1 ± 2.6

<0.0001

Weight, kg

60.1 ± 11.7

55.3 ± 9.8

<0.0001

59.6 ± 11.6

55.3 ± 9.8

<0.0001

BMI, kg/m2

22.5 ± 3.6

22.0 ± 3.1

0.0070

22.4 ± 3.5

22.0 ± 3.2

0.1712

ECOG PS, n (%)

   0

1682 (66.3)

401 (57.0)

<0.0001

227 (57.2)

225 (56.7)

0.8758

   1

733 (28.9)

261 (37.1)

142 (35.8)

147 (37.0)

   ≥2

121 (4.8)

41 (5.8)

28 (7.1)

25 (6.3)

   eGFR (mL/min/1.73 m2)

55.9 ± 22.0

47.9 ± 17.6

<0.0001

53.7 ± 19.5

47.5 ± 15.5

<0.0001

TNM stage, n (%)

   I

8 (0.3)

9 (1.3)

<0.0001

0 (0.0)

1 (0.3)

0.5297

   II

5 (0.2)

4 (0.6)

0 (0.0)

1 (0.3)

   III

27 (1.1)

18 (2.6)

2 (0.5)

3 (0.8)

   IV

2492 (98.3)

672 (95.6)

395 (99.5)

392 (98.7)

   Unknown

4 (0.2)

0 (0.0)

0 (0.0)

0 (0.0)

   Prior surgery, n (%) yes/no

2139 (84.4) / 397 (15.7)

564 (80.2) / 139 (19.8)

0.0093

365 (91.9) / 32 (8.1)

367 (92.4) / 30 (7.6)

0.7914

Prior systemic anticancer therapy, n (%)

   Any

2034 (80.2)

538 (76.5)

0.0330

330 (83.1)

330 (83.1)

1.0000

   No

502 (19.8)

165 (23.5)

67 (16.9)

67 (16.9)

Primary diseasea, n (%)

   Unresectable/metastatic RCC

2502 (98.7)

698 (99.3)

0.1757

397 (100.0)

397 (100.0)

1.0000

   Other than unresectable/metastatic RCC

40 (1.6)

7 (1.0)

0.2539

0 (0.0)

0 (0.0)

1.0000

Subtype, n (%)

   Clear cell carcinoma

1867 (73.6)

497 (70.7)

0.3599

335 (84.4)

346 (87.2)

0.2638

   Non-clear cell carcinoma

259 (10.2)

60 (8.5)

62 (15.6)

51 (12.9)

Metastatic site, n (%)

   Any

2472 (97.5)

670 (95.3)

0.0028

392 (98.7)

387 (97.5)

0.1925

   Bone

823 (32.5)

184 (26.2)

0.0015

106 (26.7)

115 (29.0)

0.4761

   Brain

144 (5.7)

25 (3.6)

0.0252

19 (4.8)

17 (4.3)

0.7330

   Liver

405 (16.0)

87 (12.4)

0.0188

48 (12.1)

48 (12.1)

1.0000

   Lung

1809 (71.3)

491 (69.8)

0.4413

293 (73.8)

288 (72.5)

0.6888

   Lung only

628 (24.8)

211 (30.0)

131 (33.0)

124 (31.2)

   Kidney

187 (7.4)

50 (7.1)

0.8138

27 (6.8)

32 (8.1)

0.4987

   Other (including lymph nodes)

1115 (44.0)

287 (40.8)

0.1368

164 (41.3)

152 (38.3)

0.3843

   AST (IU/L)

26.5 ± 31.1

24.9 ± 17.6

0.2353

25.5 ± 21.0

25.0 ± 18.5

0.7668

   ALT (IU/L)

24.2 ± 28.5

20.0 ± 20.6

0.0006

23.8 ± 27.4

20.3 ± 23.0

0.0563

   T-Bil (mg/dL)

0.55 ± 0.34

0.57 ± 0.61

0.4028

0.55 ± 0.32

0.57 ± 0.62

0.6742

   LDH (mg/dL)

229.3 ± 260.1

225.9 ± 208.1

0.7711

207.5 ± 118.4

220.0 ± 228.5

0.3432

   CRP, mg/dL

3.15 ± 5.20

2.53 ± 4.01

0.0122

2.19 ± 3.98

2.30 ± 3.98

0.7145

MSKCC risk (1999)b, n (%)

   Favourable

451 (17.8)

87 (12.4)

0.0066

81 (20.4)

70 (17.6)

0.1443

   Intermediate

1413 (55.7)

414 (58.9)

265 (66.8)

259 (65.2)

   Poor

143 (5.6)

35 (5.0)

18 (4.5)

14 (3.5)

  1. Data are expressed as mean ± SD unless otherwise indicated.
  2. BMI body mass index, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR estimated glomerular filtration rate, MSKCC Memorial Sloan Kettering Cancer Center, RCC renal cell carcinoma, TNM tumour, node, metastasis.
  3. aIncluding multiple choices.
  4. bPatients with any line of therapy
Back to article page